Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Subscribe To Our Newsletter & Stay Updated